

2026-04-13; 14:00: LhARA business plan discussion:

Present: M. Noro, C. Townsley, H. Owen, M. Gardiner, K. Long, S. Farrington, R. Pattathil, P.McIntosh

Not real notes; headlines of what we discussed/agreed and actions:

- KL presented an update on development of the LhARA initiative since last discussion of business plan. The scheme for the development of a business plan for the LhARA initiative as a plan “owned by” the 4-nation/international collaboration that will allow each stakeholder to develop its own business plan to demonstrate its role in the overall initiative was outlined. The importance of this way of formalising the initiative in order to raise resource in a “portfolio” approach was recognised.
 - The slides presented (with the embarrassing cut and paste error corrected) are attached.
 - There was consensus on the value of the LhARA initiative and on the proposed approach to the development of business plan(s).
 - The discussion included a variety of comments; key points noted:
 - Require benefits map;
 - C. Townsley/PPD project office able to support to get things going, but, need to find modest resources to allow continued engagement (**Action: KL/MN**)
 - Discussion of possible synergy with proton clinical linac development at DL was possible. P.McI commented that the recommissioning of the AVO linac was being considered by Leora Technologies with a view to the eventual development of a patient-treatment facility. It was recognised that the proton linac might have value as part of a development pipeline that allowed items to be demonstrated prior to exploitation at Christie or UCLH or for biological exposures and the development of technique.
- **Agreed:**
 - Merit of the initiative justified the development of the business plan and other documents. This would be taken forward by KL & CT in consultation with STFC departments and the LhARA collaboration (**Action: KL/CT**).